Recommendation of the President – Abrysvo (respiratory syncytial virus vaccine bivalent, recombinant)
On 13 November 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 124/2024 Abrysvo (respiratory syncytial virus vaccine bivalent, recombinant) on the appraisal of Abrysvo (respiratory syncytial virus vaccine bivalent, recombinant) for the indication: active immunization of persons 60 years of age and older against lower respiratory tract diseases caused by RSV virus